Ivermectin has been given to hundreds of millions of people since the late 1980s, primarily to treat parasitic diseases in the developing world, with a safety record that is unusually well documented for a drug of its age. That record is not an accident of luck. It rests on a specific, well-understood piece of human biology: a molecular pump called P-glycoprotein, stationed at the blood-brain barrier, that keeps the drug from accumulating where it could do harm. This article explains what P-glycoprotein is, how it protects the brain, what happens when that protection fails, and what the evidence actually shows about ivermectin's safety at approved doses versus its use outside approved indications.
A Gift from the Soil: Discovery and Approved Use
Ivermectin's origin is a genuine scientific story worth knowing. In the 1970s, Satoshi Ōmura, a microbiologist at Japan's Kitasato Institute, cultured a soil bacterium, Streptomyces avermitilis, collected near a golf course outside Tokyo. Working with William Campbell at Merck, researchers isolated and modified the bacterium's natural compounds into avermectin and then ivermectin. The two men shared the 2015 Nobel Prize in Physiology or Medicine for the discovery, alongside Tu Youyou's work on artemisinin. It is a reminder that some of medicine's most consequential tools have come not from a laboratory bench alone but from the ordinary soil, in a world whose ordered complexity keeps yielding useful surprises to those who look carefully.
Ivermectin is approved by the FDA for onchocerciasis (river blindness) and intestinal strongyloidiasis, and topical formulations are approved for head lice and rosacea. Since 1987, Merck has donated the drug through the Mectizan Donation Program, coordinated with the World Health Organization, distributing well over a billion cumulative treatments for river blindness and lymphatic filariasis across Africa and Latin America. That program is frequently cited in public health literature as one of the more successful mass drug administration efforts on record, and the scale of exposure it represents is a major reason ivermectin's human safety profile at approved doses is considered well characterized.
The Blood-Brain Barrier and P-glycoprotein: Nature's Doorman
The blood-brain barrier is a layer of tightly joined endothelial cells lining the brain's blood vessels, engineered by the body to keep most circulating substances out of neural tissue while letting oxygen, glucose, and select nutrients through. It is one of the more elegant protective structures in human physiology. Embedded in those endothelial cell membranes is P-glycoprotein, an efflux transporter encoded by the ABCB1 gene (also called MDR1). P-glycoprotein works like a doorman running in reverse: rather than letting things in, it actively grabs certain molecules that manage to enter the endothelial cell and pumps them back out into the bloodstream, using energy from ATP to do it.
Ivermectin is a known substrate of P-glycoprotein, meaning it is one of the molecules this pump is built to recognize and expel. Laboratory studies using cell membrane vesicles and P-glycoprotein-expressing cell lines, dating back to pharmacology work in the 1990s, established that ivermectin binds the transporter efficiently. In a person with normally functioning P-glycoprotein, ivermectin that crosses into brain capillary endothelium is largely pumped back out before it can accumulate in neural tissue in meaningful concentrations. This is the central mechanistic reason ivermectin, despite acting on chloride channels found in invertebrate and some vertebrate neurons, does not produce significant central nervous system depression in most humans at approved doses: the drug's target cells in the brain are substantially shielded from it.
What Collie Dogs Taught Us About Drug Safety
The clearest demonstration of what happens when this pump fails comes not from human medicine but from veterinary genetics, and it is worth understanding because it shows the mechanism is real rather than theoretical. Certain dog breeds, most notably rough-coated Collies, have long been known to suffer severe neurological toxicity, including tremors, ataxia, coma, and occasionally death, from ivermectin doses that other dogs tolerate without difficulty. In 2001, Katrina Mealey and colleagues at Washington State University published research in the journal Pharmacogenetics identifying the cause: a four-base-pair deletion in the ABCB1 gene, producing a nonfunctional, truncated P-glycoprotein. Roughly three-quarters of rough-coated Collies carry this mutation. Without a working efflux pump at their blood-brain barrier, ivermectin accumulates in their brains at concentrations many times higher than in dogs with normal P-glycoprotein, and toxicity follows.
This finding did two things for the broader scientific understanding of the drug. First, it confirmed, in a living animal model, that P-glycoprotein function is the deciding variable between safety and neurotoxicity with ivermectin, not the drug's dose alone. Second, it clarified that ivermectin itself is not inherently a "brain toxin" waiting to happen; it is a drug whose access to the brain depends entirely on a specific, identifiable transporter working correctly. Humans do not carry an equivalent of the Collie ABCB1 deletion as a common population variant, which is part of why this particular toxicity pattern is not seen in ordinary human use.
Why Human Dosing Matters: Metabolism, Overdose, and Formulation
None of this means ivermectin is risk-free or that dose is irrelevant in humans; it means the margin of safety at approved doses is unusually well supported by the underlying biology. In humans, ivermectin is absorbed orally, binds plasma proteins heavily (around 93%), is metabolized primarily by the liver enzyme CYP3A4, and has an elimination half-life of roughly 18 hours. At the doses used for onchocerciasis and strongyloidiasis (typically single or short-course dosing based on body weight), plasma and brain concentrations remain within a range where P-glycoprotein efflux keeps CNS exposure low.
Case reports of human ivermectin toxicity, published in toxicology literature over the years, generally involve substantially higher-than-approved doses, often from accidental or intentional overdose, and describe symptoms consistent with excess CNS exposure: dizziness, tremor, ataxia, and, in severe cases, seizures or coma. The FDA has separately and repeatedly warned against taking veterinary ivermectin formulations intended for livestock, because these products are manufactured at much higher concentrations for large animals and are not formulated, dosed, or purified to human pharmaceutical standards. Poison control centers in the United States reported a marked rise in calls related to ivermectin misuse during 2020 and 2021, the large majority tied to people obtaining animal-labeled products rather than physician-prescribed human formulations. This is a formulation and dosing problem, not evidence against the underlying pharmacology described above.
There is also a genuine pharmacological caution worth naming plainly: drugs or substances that inhibit P-glycoprotein could, in principle, reduce the brain's ability to exclude ivermectin, raising the theoretical risk of CNS effects even at otherwise standard doses. This interaction is documented mechanistically and in animal studies rather than as a large body of human outcome data, and it is one of several reasons ivermectin should be used under a physician's guidance who knows a patient's full medication list, rather than self-directed.
Ivermectin, COVID-19, and the Difference Between Safety and Efficacy
It is important to separate two distinct questions that were often blurred in public discussion: whether ivermectin is safe at approved doses, and whether it is effective for uses it is not approved for. Ivermectin is not approved by the FDA, or by equivalent regulators elsewhere, for the prevention or treatment of COVID-19. Several sizable randomized controlled trials examined the question directly. The TOGETHER trial, an adaptive platform trial run across Brazilian and Canadian research centers and published in the New England Journal of Medicine in 2022, found no significant reduction in COVID-19 hospitalization among outpatients given ivermectin compared to placebo. The ACTIV-6 trial, funded by the National Institutes of Health and published in JAMA in 2022, similarly found no meaningful improvement in time to recovery among outpatients with mild-to-moderate COVID-19. These are real, peer-reviewed, adequately powered human trials, and their consistent finding of no clear clinical benefit for this particular use is worth stating plainly rather than minimizing.
The safety mechanism described in this article, P-glycoprotein's protection of the brain, remains accurate regardless of what any given trial found about efficacy for a specific illness. A drug can have a well-characterized and favorable safety profile at its approved indications while still lacking evidence of benefit for an unapproved one. Readers deserve both pieces of information stated honestly, without either being used to obscure the other.
Informed Consent and the Case for Working With Your Own Physician
The responsible way to think about any medication, ivermectin included, is to understand what it does, why it behaves as it does in the body, and where the edges of the evidence lie, and then to make a decision in partnership with a physician who knows your history and current medications. That is what informed consent actually means in practice, and it is worth more than either blanket reassurance or blanket alarm. Parents managing a child's scabies infestation, a returning traveler with strongyloidiasis, or a patient in a river blindness program abroad are all being treated with a drug whose mechanism of safety is unusually well mapped at the molecular level, from soil bacterium to Nobel Prize to a specific transporter protein doing its quiet, constant work at the blood-brain barrier. Respecting that biology, and respecting the dosing and formulation it was studied under, is simply good stewardship of a body worth caring for properly.
Key takeaway: Ivermectin's strong human safety record at approved doses is grounded in a specific, well-documented mechanism, the P-glycoprotein pump that shields the brain, and that mechanism is separate from the unresolved question of the drug's efficacy for uses outside its approved indications.